Risk Analysis of Distal Metastasis in Chondrosarcoma and the Development and Validation of a Novel Clinical Prediction Model: A Clinical Study Based on the SEER Database

Table 2

Baseline of chondrosarcoma patients without and with metastases.

Variable	Level	Overall (N = 1290)	M0 (N = 1215)	M1 (N = 75)
Race (%)	Black	96 (7.4)	90 (7.4)	6 (8.0)	0.752
	Other	77 (6.0)	74 (6.1)	3 (4.0)
	White	1117 (86.6)	1051 (86.5)	66 (88.0)
Age (mean (SD))	NA	53.44 (18.12)	52.96 (18.06)	61.16 (17.43)	<0.001
Sex (%)	Female	571 (44.3)	550 (45.3)	21 (28.0)	0.005
	Male	719 (55.7)	665 (54.7)	54 (72.0)
Primary site (%)	Axis bone	677 (52.5)	629 (51.8)	48 (64.0)	0.068
	Bone of limb	544 (42.2)	522 (43.0)	22 (29.3)
	Other	69 (5.3)	64 (5.3)	5 (6.7)
Laterality (%)	Left	496 (38.4)	482 (39.7)	14 (18.7)	0.001
	Not a paired site	293 (22.7)	268 (22.1)	25 (33.3)
	Right	501 (38.8)	465 (38.3)	36 (48.0)
Grade (%)	Moderately differentiated; grade II	518 (40.2)	492 (40.5)	26 (34.7)	<0.001
	Poorly differentiated; grade III	129 (10.0)	115 (9.5)	14 (18.7)
	Undifferentiated; anaplastic; grade IV	39 (3.0)	32 (2.6)	7 (9.3)
	Unknown	169 (13.1)	146 (12.0)	23 (30.7)
	Well differentiated; grade I	435 (33.7)	430 (35.4)	5 (6.7)
T (%)	T1	716 (55.5)	704 (57.9)	12 (16.0)	<0.001
	T2	389 (30.2)	351 (28.9)	38 (50.7)
	T3	13 (1.0)	9 (0.7)	4 (5.3)
	TX	172 (13.3)	151 (12.4)	21 (28.0)
N (%)	N0	1237 (95.9)	1178 (97.0)	59 (78.7)	<0.001
	N1	11 (0.9)	5 (0.4)	6 (8.0)
	NX	42 (3.3)	32 (2.6)	10 (13.3)
Surgery (%)	No	177 (13.7)	133 (10.9)	44 (58.7)	<0.001
	Yes	1113 (86.3)	1082 (89.1)	31 (41.3)
Lymph node dissection (%)	No	1213 (94.0)	1142 (94.0)	71 (94.7)	1
	Yes	77 (6.0)	73 (6.0)	4 (5.3)
Radiation (%)	No	1149 (89.1)	1081 (89.0)	68 (90.7)	0.79
	Yes	141 (10.9)	134 (11.0)	7 (9.3)
Chemotherapy (%)	No/unknown	1231 (95.4)	1181 (97.2)	50 (66.7)	<0.001
	Yes	59 (4.6)	34 (2.8)	25 (33.3)
Survival months (mean (SD))	NA	34.19 (24.16)	35.38 (24.00)	14.99 (18.03)	<0.001